Relaxin-3/RXFP3 networks: An emerging target for the treatment of depression and other neuropsychiatric diseases?

Frontiers in Pharmacology

Volumn 5 MAR, Issue , 2014, Pages

  Smith, Craig M ^a,b   Walker, Andrew W ^a,b   Hosken, Ihaia T ^a,b   Chua, Berenice E ^a   Zhang, Cary ^a,b   Haidar, Mouna ^a,b   Gundlach, Andrew L ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Arousal; Autism spectrum disorders; Eating disorders; Mood and depression; Neuropeptide; Relaxin 3; RXFP3; Stress

Indexed keywords

NEUROPEPTIDE RECEPTOR; RELAXIN 3; RELAXIN FAMILY PEPTIDE 3 RECEPTOR; RELAXIN FAMILY PEPTIDE 3 RECEPTOR AGONIST; RELAXIN FAMILY PEPTIDE 3 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANOREXIA NERVOSA; ANXIETY DISORDER; AUTISM; BRAIN FUNCTION; BRAIN REGION; DRUG TARGETING; HIPPOCAMPUS; HUMAN; INTERPEDUNCULAR NUCLEUS; MAJOR DEPRESSION; MEDIAL SEPTUM; NERVE CELL; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OBESITY; POSTERIOR HYPOTHALAMUS; REVIEW; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; STRESS; SUPRAMAMMILLARY NUCLEUS;

EID: 84897929309     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00046     Document Type: Review

References (242)

1. Abbott, A. (2013). Novartis reboots brain division. Nature 502, 153-154. doi: 10.1038/502153a.
2. Adan, R. A. H. (2013). Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 36, 133-140. doi: 10.1016/j.tins.2012.12.001.
3. Adrien, J. (2002). Neurobiological basis for the relation between sleep and depression. Sleep Med. Rev. 6, 341-351.
4. Alam, M. N., Kumar, S., Bashir, T., Suntsova, N., Methippara, M. M., Szymusiak, R., et al. (2005). GABA-mediated control of hypocretin-but not melanin-concentrating hormone-immunoreactive neurones during sleep in rats. J. Physiol. (Lond.) 563, 569-582. doi: 10.1113/jphysiol.2004.076927.
5. Albers, H. E., Ottenweller, J. E., Liou, S. Y., Lumpkin, M. D., and Anderson, E. R. (1990). Neuropeptide Y in the hypothalamus: effect on corticosterone and single-unit activity. Am. J. Physiol. 258, R376-R382.
6. Alvarez-Jaimes, L., Sutton, S. W., Nepomuceno, D., Motley, S. T., Cik, M., Stocking, E., et al. (2012). In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependency. PLoS ONE 7:e30792. doi: 10.1371/journal.pone.0030792.
7. Amaral, D. G., Bauman, M. D., Capitanio, J. P., Lavenex, P., Mason, W. A., Mauldin-Jourdain, M. L., et al. (2003). The amygdala: is it an essential component of the neural network for social cognition? Neuropsychologia 41, 517-522. doi: 10.1016/S0028-3932(02)00310-X.
8. Anand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, L., et al. (2005). Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol. Psychiatry 57, 1079-1088. doi: 10.1016/j.biopsych.2005.02.021.
9. Antonijevic, I. A., Murck, H., Bohlhalter, S., Frieboes, R. M., Holsboer, F., and Steiger, A. (2000). Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 39, 1474-1481. doi: 10.1016/S0028-3908(00)00057-5.
10. Arborelius, L., Owens, M. J., Plotsky, P. M., and Nemeroff, C. B. (1999). The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160, 1-12. doi: 10.1677/joe.0.1600001.
11. Argyropoulos, S. V., and Wilson, S. J. (2005). Sleep disturbances in depression and the effects of antidepressants. Int. Rev. Psychiatry 17, 237-245. doi: 10.1080/09540260500104458.
12. Atasoy, D., Betley, J. N., Su, H. H., and Sternson, S. M. (2012). Deconstruction of a neural circuit for hunger. Nature 488, 172-177. doi: 10.1038/nature11270.
13. Bailey, J. E., Papadopoulos, A., Diaper, A., Phillips, S., Schmidt, M., van der Ark, P., et al. (2011). Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. J. Psychopharmacol. 25, 1199-1206. doi: 10.1177/0269881111400650.
14. Banerjee, A., Ma, S., Ortinau, S., Smith, C. M., Layfield, S., Burazin, T. C. D., et al. (2005). Relaxin-3 neurons in the nucleus incertus-projection patterns, response to swim stress and relaxin-3 neuronal signalling. Soc. Neurosci. Abstr. 35, 59.57.
15. Banerjee, A., Shen, P.-J., Ma, S., Bathgate, R. A. D., and Gundlach, A. L. (2010). Swim stress excitation of nucleus incertus and rapid induction of relaxin-3 expression via CRF1 activation. Neuropharmacology 58, 145-155. doi: 10.1016/j.neuropharm.2009.06.019.
16. Bathgate, R. A. D., Halls, M. L., van der Westhuizen, E. T., Callander, G. E., Kocan, M., and Summers, R. J. (2013a). Relaxin family peptides and their receptors. Physiol. Rev. 93, 405-480. doi: 10.1152/physrev.00001.2012.
17. Bathgate, R. A. D., Oh, M. H., Ling, W. J., Kaas, Q., Hossain, M. A., Gooley, P. R., et al. (2013b). Elucidation of relaxin-3 binding interactions in the extracellular loops of RXFP3. Front. Endocrinol. (Lausanne) 4:13. doi: 10.3389/fendo.2013.00013.
18. Bathgate, R. A. D., Ivell, R., Sanborn, B. M., Sherwood, O. D., and Summers, R. J. (2006). International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol. Rev. 58, 7-31. doi: 10.1124/pr.58.1.9.
19. Bathgate, R. A. D., Samuel, C. S., Burazin, T. C. D., Layfield, S., Claasz, A. A., Reytomas, I. G., et al. (2002). Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. J. Biol. Chem. 277, 1148-1157. doi: 10.1074/jbc.M107882200.
20. Bauman, M. L., and Kemper, T. L. (2005). Neuroanatomic observations of the brain in autism: a review and future directions. Int. J. Dev. Neurosci. 23, 183-187. doi: 10.1016/j.ijdevneu.2004.09.006.
21. Berger, M., Van Calker, D., and Riemann, D. (2003). Sleep and manipulations of the sleep-wake rhythm in depression. Acta Psychiatr. Scand. 108, 83-91. doi: 10.1034/j.1600-0447.108.s418.17.x.
22. Berridge, C. W., Schmeichel, B. E., and España, R. A. (2012). Noradrenergic modulation of wakefulness/arousal. Sleep Med. Rev. 16, 187-197. doi: 10.1016/j.smrv.2011.12.003.
23. Bespalova, I. N., Angelo, G. W., Durner, M., Smith, C. J., Siever, L. J., Buxbaum, J. D., et al. (2005). Fine mapping of the 5p13 locus linked to schizophrenia and schizotypal personality disorder in a Puerto Rican family. Psychiatry Genet. 15, 205-210. doi: 10.1097/00041444-200509000-00012.
24. Bing, O., Möller, C., Engel, J. A., Soderpalm, B., and Heilig, M. (1993). Anxiolytic-like action of centrally administered galanin. Neurosci. Lett. 164, 17-20. doi: 10.1016/0304-3940(93)90846-D.
25. Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., and Stiger, T. (2008). A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165, 617-620. doi: 10.1176/appi.ajp.2008.07071199.
26. Bishop-Fitzpatrick, L., Minshew, N. J., and Eack, S. M. (2013). A systematic review of psychosocial interventions for adults with autism spectrum disorders. J. Autism Dev. Disord. 43, 687-694. doi: 10.1007/s10803-012-1615-8.
27. Bittencourt, J. C. (2011). Anatomical organization of the melanin-concentrating hormone peptide family in the mammalian brain. Gen. Comp. Endocrinol. 172, 185-197. doi: 10.1016/j.ygcen.2011.03.028.
28. Bittencourt, J. C. (2013). The tale of a person and a peptide: Wylie W. Vale Jr. and the role of corticotropin-releasing factor in the stress response. J. Chem. Neuroanat. 54, 1-4. doi: 10.1016/j.jchemneu.2013.04.005.
29. Bittencourt, J. C., and Sawchenko, P. E. (2000). Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system. J. Neurosci. 20, 1142-1156.
30. Blasiak, A., Blasiak, T., Lewandowski, M. H., Hossain, M. A., Wade, J. D., and Gundlach, A. L. (2013). Relaxin-3 innervation of the intergeniculate leaflet of the rat thalamus-neuronal tract-tracing and in vitro electrophysiological studies. Eur. J. Neurosci. 37, 1284-1294. doi: 10.1111/ejn.12155.
31. Blasiak, A., Gundlach, A. L., and Lewandowski, M. H. (2010). Orexins increase nucleus incertus neuronal activity: implications for a possible reinforcing arousal drive. FENS Abstr. 5, 104.2.
32. Boels, K., Hermans-Borgmeyer, I., and Schaller, H. C. (2004). Identification of a mouse orthologue of the G-protein-coupled receptor SALPR and its expression in adult mouse brain and during development. Dev. Brain Res. 152, 265-268. doi: 10.1016/j.devbrainres.2004.06.002.
33. Brundin, L., Bjorkqvist, M., Petersen, A., and Traskman-Bendz, L. (2007). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 17, 573-579. doi: 10.1016/j.euroneuro.2007.01.005.
34. Burazin, T. C. D., Bathgate, R. A. D., Macris, M., Layfield, S., Gundlach, A. L., and Tregear, G. W. (2002). Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain. J. Neurochem. 82, 1553-1557. doi: 10.1046/j.1471-4159.2002.01114.x.
35. Burgess, C. R., and Scammell, T. E. (2012). Narcolepsy: neural mechanisms of sleepiness and cataplexy. J. Neurosci. 32, 12305-12311. doi: 10.1523/JNEUROSCI.2630-12.2012.
36. Burt, J., Alberto, C. O., Parsons, M. P., and Hirasawa, M. (2011). Local network regulation of orexin neurons in the lateral hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R572-R580. doi: 10.1152/ajpregu.00674.2010.
37. Caldwell, H. K., Lee, H. J., Macbeth, A. H., and Young, W. S. III. (2008). Vasopressin: behavioral roles of an "original" neuropeptide. Prog. Neurobiol. 84, 1-24. doi: 10.1016/j.pneurobio.2007.10.007.
38. Callander, G. E., Ma, S., Ganella, D. E., Wimmer, V. C., Gundlach, A. L., Thomas, W. G., et al. (2012). Silencing relaxin-3 in nucleus incertus of adult rodents: a viral vector-based approach to investigate neuropeptide function. PLoS ONE 7:e42300. doi: 10.1371/journal.pone.0042300.
39. Carter, R., Mouralidarane, A., Ray, S., Soeda, J., and Oben, J. (2012). Recent advancements in drug treatment of obesity. Clin. Med. 12, 456-460. doi: 10.7861/clinmedicine.12-5-456.
40. Castle, D., Keks, N., Newton, R., Schweitzer, I., Copolov, D., Paoletti, N., et al. (2013). Pharmacological approaches to the management of schizophrenia: 10 years on. Australas Psychiatry 21, 329-334. doi: 10.1177/1039856213486211.
41. Cervera-Ferri, A., Guerrero-Martinez, J., Bataller-Mompean, M., Taberner-Cortes, A., Martinez-Ricos, J., Ruiz-Torner, A., et al. (2011). Theta synchronization between the hippocampus and the nucleus incertus in urethane-anesthetized rats. Exp. Brain Res. 211, 177-192. doi: 10.1007/s00221-011-2666-3.
42. Cervera-Ferri, A., Rahmani, Y., Martinez-Bellver, S., Teruel-Marti, V., and Martinez-Ricos, J. (2012). Glutamatergic projection from the nucleus incertus to the septohippocampal system. Neurosci. Lett. 517, 71-76. doi: 10.1016/j.neulet.2012.04.014.
43. Challis, C., Boulden, J., Veerakumar, A., Espallergues, J., Vassoler, F. M., Pierce, R. C., et al. (2013). Raphe GABAergic neurons mediate the acquisition of avoidance after social defeat. J. Neurosci. 33, 13978-13988. doi: 10.1523/JNEUROSCI.2383-13.2013.
44. Chalmers, D. T., Lovenberg, T. W., and De Souza, E. B. (1995). Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15, 6340-6350.
45. Chan, L. J., Smith, C. M., Chua, B. E., Lin, F., Bathgate, R. A. D., Separovic, F., et al. (2013). Synthesis of fluorescent analogues of relaxin family peptides and their preliminary in vitro and in vivo characterization. Front. Chem. 1:30. doi: 10.3389/fchem.2013.00030.
46. Chee, M. J. S., Pissios, P., and Maratos-Flier, E. (2013). Neurochemical characterization of neurons expressing melanin-concentrating hormone receptor 1 in the mouse hypothalamus. J. Comp. Neurol. 521, 2208-2234. doi: 10.1002/cne.23273.
47. Clark, L., Chamberlain, S. R., and Sahakian, B. J. (2009). Neurocognitive mechanisms in depression: implications for treatment. Ann. Rev. Neurosci. 32, 57-74. doi: 10.1146/annurev.neuro.31.060407.125618.
48. Crawley, J. N., Hays, S. E., O'Donohue, T. L., Paul, S. M., and Goodwin, F. K. (1981). Neuropeptide modulation of social and exploratory behaviors in laboratory rodents. Peptides 2(Suppl. 1), 123-129. doi: 10.1016/0196-9781(81)90066-8.
49. Crestani, C. C., Alves, F. H. F., Gomes, F. V., Resstel, L. B. M., Correa, F. M. A., and Herman, J. P. (2013). Mechanisms in the bed nucleus of the stria terminalis involved in control of autonomic and neuroendocrine functions: a review. Curr. Neuropharmacol. 11, 141-159. doi: 10.2174/1570159X11311020002.
50. Cummings, S., Elde, R., Ells, J., and Lindall, A. (1983). Corticotropin-releasing factor immunoreactivity is widely distributed within the central nervous system of the rat: an immunohistochemical study. J. Neurosci. 3, 1355-1368.
51. Dabrowska, J., Hazra, R., Guo, J.-D., Witt, S. D., and Rainnie, D. G. (2013). Central CRF neurons are not created equal: phenotypic differences in CRF-containing neurons of the rat paraventricular hypothalamus and the bed nucleus of the stria terminalis. Front. Neurosci. 7:156. doi: 10.3389/fnins.2013.00156.
52. de Wit, R., Herrstedt, J., Rapoport, B., Carides, A. D., Guoguang-Ma, J., Elmer, M., et al. (2004). The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur. J. Cancer 40, 403-410. doi: 10.1016/S0959-8049(03)00931-6.
53. Dimitrov, E. L., DeJoseph, M. R., Brownfield, M. S., and Urban, J. H. (2007). Involvement of neuropeptide Y Y1 receptors in the regulation of neuroendocrine corticotropin-releasing hormone neuronal activity. Endocrinology 148, 3666-3673. doi: 10.1210/en.2006-1730.
54. Domschke, K., Reif, A., Weber, H., Richter, J., Hohoff, C., Ohrmann, P., et al. (2011). Neuropeptide S receptor gene-converging evidence for a role in panic disorder. Mol. Psychiatry 16, 938-948. doi: 10.1038/mp.2010.81.
55. Dore, R., Iemolo, A., Smith, K. L., Wang, X., Cottone, P., and Sabino, V. (2013). CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP. Neuropsychopharmacology 38, 2160-2169. doi: 10.1038/npp.2013.113.
56. Dunn, J. D. (1987). Plasma corticosterone responses to electrical stimulation of the bed nucleus of the stria terminalis. Brain Res. 407, 327-331. doi: 10.1016/0006-8993(87)91111-5.
57. Espejo, E. F., and Minano, F. J. (1999). Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test. Neuroscience 88, 609-615. doi: 10.1016/S0306-4522(98)00258-9.
58. Fan, J., Bernardi, S., Dam, N. T., Anagnostou, E., Gu, X., Martin, L., et al. (2012). Functional deficits of the attentional networks in autism. Brain Behav. 2, 647-660. doi: 10.1002/brb3.90.
59. Farooq, U., Rajkumar, R., Sukumaran, S., Wu, Y., Tan, W. H., and Dawe, G. S. (2013). Corticotropin-releasing factor infusion into nucleus incertus suppresses medial prefrontal cortical activity and hippocampo-medial prefrontal cortical long-term potentiation. Eur. J. Neurosci. 38, 2516-2525. doi: 10.1111/ejn.12242.
60. Farrella, M. S., and Roth, B. L. (2013). Pharmacosynthetics: reimagining the pharmacogenetic approach. Brain Res. 1511, 6-20. doi: 10.1016/j.brainres.2012.09.043.
61. File, S. E., and Seth, P. (2003). A review of 25 years of the social interaction test. Eur. J. Pharmacol. 463, 35-53. doi: 10.1016/S0014-2999(03)01273-1.
62. Furutani, N., Hondo, M., Kageyama, H., Tsujino, N., Mieda, M., Yanagisawa, M., et al. (2013). Neurotensin co-expressed in orexin-producing neurons in the lateral hypothalamus plays an important role in regulation of sleep/wakefulness states. PLoS ONE 8:e62391. doi: 10.1371/journal.pone.0062391.
63. Ganella, D. E., Callander, G. E., Ma, S., Bye, C. R., Gundlach, A. L., and Bathgate, R. A. D. (2013a). Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus. Gene Ther. 20, 703-716. doi: 10.1038/gt.2012.83.
64. Ganella, D. E., Ma, S., and Gundlach, A. L. (2013b). Relaxin-3/RXFP3 signaling and neuroendocrine function-a perspective on extrinsic hypothalamic control. Front. Endocrinol. (Lausanne) 4:128. doi: 10.3389/fendo.2013.00128.
65. Ganella, D. E., Ryan, P. J., Bathgate, R. A. D., and Gundlach, A. L. (2012). Increased feeding and body weight gain after acute/chronic hypothalamic activation of RXFP3 by relaxin-3 and receptor-selective synthetic and rAAV-driven agonist peptides: functional and therapeutic implications. Behav. Pharmacol. 23, 516-525. doi: 10.1097/FBP.0b013e3283576999.
66. Gaus, S. E., Strecker, R. E., Tate, B. A., Parker, R. A., and Saper, C. B. (2002). Ventrolateral preoptic nucleus contains sleep-active, galaninergic neurons in multiple mammalian species. Neuroscience 115, 285-294. doi: 10.1016/S0306-4522(02)00308-1.
67. Goto, M., Swanson, L. W., and Canteras, N. S. (2001). Connections of the nucleus incertus. J. Comp. Neurol. 438, 86-122. doi: 10.1002/cne.1303.
68. Hangya, B., Borhegyi, Z., Szilágyi, N., Freund, T. F., and Varga, V. (2009). GABAergic neurons of the medial septum lead the hippocampal network during theta activity. J. Neurosci. 29, 8094-8102. doi: 10.1523/JNEUROSCI.5665-08.2009.
69. Harrington, M. E. (1997). The ventral lateral geniculate nucleus and the intergeniculate leaflet: interrelated structures in the visual and circadian systems. Neurosci. Biobehav. Rev. 21, 705-727. doi: 10.1016/S0149-7634(96)00019-X.
70. Hastings, M. H., and Goedert, M. (2013). Circadian clocks and neurodegenerative diseases: time to aggregate? Curr. Opin. Neurobiol. 23, 1-8. doi: 10.1016/j.conb.2013.05.004.
71. Haugaard-Jonsson, L. M., Hossain, M. A., Daly, N. L., Bathgate, R. A. D., Wade, J. D., Craik, D. J., et al. (2008). Structure of the R3/I5 chimeric relaxin peptide, a selective GPCR135 and GPCR142 agonist. J. Biol. Chem. 283, 23811-23818. doi: 10.1074/jbc.M800489200.
72. Haznedar, M. M., Buchsbaum, M. S., Wei, T. C., Hof, P. R., Cartwright, C., Bienstock, C. A., et al. (2000). Limbic circuitry in patients with autism spectrum disorders studied with positron emission tomography and magnetic resonance imaging. Am. J. Psychiatry 157, 1994-2001. doi: 10.1176/appi.ajp.157.12.1994.
73. Held, K., Antonijevic, I., Murck, H., Kuenzel, H., and Steiger, A. (2006). Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrinology 31, 100-107. doi: 10.1016/j.psyneuen.2005.05.015.
74. Hida, T., Takahashi, E., Shikata, K., Hirohashi, T., Sawai, T., Seiki, T., et al. (2006). Chronic intracerebroventricular administration of relaxin-3 increases body weight in rats. J. Recept. Signal Transduct. Res. 26, 147-158. doi: 10.1080/10799890600623373.
75. Hisaw, F. L. (1926). Experimental relaxation of the pubic ligament of the guinea pig. Proc. Soc. Exp. Biol. Med. 23, 661-663. doi: 10.3181/00379727-23-3107.
76. Hökfelt, T., Bartfai, T., and Bloom, F. (2003). Neuropeptides: opportunities for drug discovery. Lancet Neurol. 2, 463-472. doi: 10.1016/S1474-4422(03)00482-4.
77. Hökfelt, T., Broberger, C., Xu, Z.-Q. D., Sergeyev, V., Ubink, R., and Diez, M. (2000). Neuropeptides-an overview. Neuropharmacology 39, 1337-1356. doi: 10.1016/S0028-3908(00)00010-1.
78. Holmes, A., Heilig, M., Rupniak, N. M., Steckler, T., and Griebel, G. (2003). Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24, 580-588. doi: 10.1016/j.tips.2003.09.011.
79. Holmes, A. J., Lee, P. H., Hollinshead, M. O., Bakst, L., Roffman, J. L., Smoller, J. W., et al. (2012). Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. J. Neurosci. 32, 18087-18100. doi: 10.1523/JNEUROSCI.2531-12.2012.
80. Hosken, I. T., Smith, C. M., Chua, B. E., and Gundlach, A. L. (2013). "Consequences of relaxin-3 null mutation in mice on food-entrainable arousal," in Proceedings of Sixth International Conference on Relaxin and Related Peptides, Florence.
81. Hossain, M. A., Smith, C. M., Ryan, P. J., Buchler, E., Bathgate, R. A. D., Gundlach, A. L., et al. (2013). Chemical synthesis and orexigenic activity of rat/mouse relaxin-3. Amino Acids 44, 1529-1536. doi: 10.1007/s00726-013-1478-0.
82. Hoyer, D., and Bartfai, T. (2012). Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof Dieter Seebach. Chem. Biodiv. 9, 2367-2387. doi: 10.1002/cbdv.201200288.
83. Hoyer, D., and Jacobson, L. H. (2013). Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? Neuropeptides 47, 477-488. doi: 10.1016/j.npep.2013.10.009.
84. Hryhorczuk, C., Sharma, S., and Fulton, S. E. (2013). Metabolic disturbances connecting obesity and depression. Front. Neurosci. 7:177. doi: 10.3389/fnins.2013.00177.
85. Insel, T., Krystal, J., and Ehlers, M. (2013a). New drug development for cognitive enhancement in mental health: challenges and opportunities. Neuropharmacology 64, 2-7. doi: 10.1016/j.neuropharm.2012.07.041.
86. Insel, T. R., Voon, V., Nye, J. S., Brown, V. J., Altevogt, B. M., Bullmore, E. T., et al. (2013b). Innovative solutions to novel drug development in mental health. Neurosci. Biobehav. Rev. 37, 2438-2444. doi.org/10.1016/j.neubiorev.2013.1003.1022.
87. Ionescu, I. A., Dine, J., Yen, Y. C., Buell, D. R., Herrmann, L., Holsboer, F., et al. (2012). Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology 37, 1323-1337. doi: 10.1038/npp.2011.317.
88. Ishida, H., Shirayama, Y., Iwata, M., Katayama, S., Yamamoto, A., Kawahara, R., et al. (2007). Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 17, 271-280. doi: 10.1002/hipo.20264.
89. Jiang, Z., Cowell, R. M., and Nakazawa, K. (2013). Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia. Front. Behav. Neurosci. 7:116. doi: 10.3389/fnbeh.2013.00116.
90. Jones, B. E., Halaris, A. E., McIlhany, M., and Moore, R. Y. (1977). Ascending projections of the locus coeruleus in the rat. I. Axonal transport in central noradrenaline neurons. Brain Res. 127, 1-21. doi: 10.1016/0006-8993(77)90377-8.
91. Kalmbach, A., Hedrick, T., and Waters, J. (2012). Selective optogenetic stimulation of cholinergic axons in neocortex. J. Neurophysiol. 107, 2008-2019. doi: 10.1152/jn.00870.2011.
92. Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., et al. (2006). Lack of efficacy of the substance P (neurokinin1 receptor) antagonist Aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59, 216-223. doi: 10.1016/j.biopsych.2005.07.013.
93. Kim, A. K., Brown, R. M., and Lawrence, A. J. (2012). The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front. Behav. Neurosci. 6:78. doi: 10.3389/fnbeh.2012.00078.
94. Kimura, M., Müller-Preuss, P., Lu, A., Wiesner, E., Flachskamm, C., Wurst, W., et al. (2010). Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol. Psychiatry 15, 154-165. doi: 10.1038/mp.2009.46.
95. Kirby, L. G., Rice, K. C., and Valentino, R. J. (2000). Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 22, 148-162. doi: 10.1016/S0893-133X(99)00093-7.
96. Kishi, T., and Elmquist, J. K. (2005). Body weight is regulated by the brain: a link between feeding and emotion. Mol. Psychiatry 10, 132-146. doi: 10.1038/sj.mp.4001638.
97. Kocsis, B., Varga, V., Dahan, L., and Sik, A. (2006). Serotonergic neuron diversity: identification of raphe neurons with discharges time-locked to the hippocampal theta rhythm. Proc. Natl. Acad. Sci. U.S.A. 103, 1059-1064. doi: 10.1073/pnas.0508360103.
98. Koob, G. F. (2010). The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res. 1314, 3-14. doi: 10.1016/j.brainres.2009.11.008.
99. Kopelman, P. G. (2000). Obesity as a medical problem. Nature 404, 635-643.
100. Kuei, C., Sutton, S., Bonaventure, P., Pudiak, C., Shelton, J., Zhu, J., et al. (2007). R3 (BΔ23-27) R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7. J. Biol. Chem. 282, 25425. doi: 10.1074/jbc.M701416200.
101. Lach, G., and de Lima, T. C. (2013). Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: dissociation between anxiety, locomotion and non-emotional memory behavior. Neurobiol. Learn. Mem. 103, 26-33. doi: 10.1016/j.nlm.2013.04.005.
102. Lebow, M., Neufeld-Cohen, A., Kuperman, Y., Tsoory, M., Gil, S., and Chen, A. (2012). Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis. J. Neurosci. 32, 6906-6916. doi: 10.1523/JNEUROSCI.4012-11.2012.
103. Lenglos, C., Mitra, A., Guevremont, G., and Timofeeva, E. (2013). Sex differences in the effects of chronic stress and food restriction on body weight gain and brain expression of CRF and relaxin-3 in rats. Genes Brain Behav. 12, 370-387. doi: 10.1111/gbb.12028.
104. Lesch, K. P., and Waider, J. (2012). Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron 76, 175-191. doi: 10.1016/j.neuron.2012.09.013.
105. Li, K., Zhou, T., Liao, L., Yang, Z., Wong, C., Henn, F., et al. (2013). βCaMKII in lateral habenula mediates core symptoms of depression. Science 341, 1016-1020. doi: 10.1126/science.1240729.
106. Lin, H. C., Gean, P. W., Wang, C. C., Chan, Y. H., and Chen, P. S. (2013). The amygdala excitatory/inhibitory balance in a valproate-induced rat autism model. PLoS ONE 8:e55248. doi: 10.1371/journal.pone.0055248.
107. Lin, L. C., and Sibille, E. (2013). Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target? Front. Pharmacol. 4:110. doi: 10.3389/fphar.2013.00110.
108. Liu, C., Chen, J., Kuei, C., Sutton, S., Nepomuceno, D., Bonaventure, P., et al. (2005). Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Mol. Pharmacol. 67, 231-240. doi: 10.1124/mol.104.006700.
109. Liu, C., Eriste, E., Sutton, S., Chen, J., Roland, B., Kuei, C., et al. (2003). Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J. Biol. Chem. 278, 50754-50764. doi: 10.1074/jbc.M308995200.
110. Liu, C., Kuei, C., Sutton, S., Shelton, J., Zhu, J., Nepomuceno, D., et al. (2009). Probing the functional domains of relaxin-3 and the creation of a selective antagonist for RXFP3/GPCR135 over relaxin receptor RXFP1/LGR7. Ann. N. Y. Acad. Sci. 1160, 31-37. doi: 10.1111/j.1749-6632.2008.03790.x.
111. Liu, T., Wang, Q., Berglund, E. D., and Tong, Q. (2013). Action of neurotransmitter: a key to unlock the AgRP neuron feeding circuit. Front. Neurosci. 6:200. doi: 10.3389/fnins.2012.00200.
112. Lukas, M., and Neumann, I. D. (2013). Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav. Brain Res. 251, 85-94. doi: 10.1016/j.bbr.2012.08.011.
113. Lukas, M., Toth, I., Reber, S. O., Slattery, D. A., Veenema, A. H., and Neumann, I. D. (2011). The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology 36, 2159-2168. doi: 10.1038/npp.2011.95.
114. Lungwitz, E. A., Molosh, A., Johnson, P. L., Harvey, B. P., Dirks, R. C., Dietrich, A., et al. (2012). Orexin-A induces anxiety-like behavior through interactions with glutamatergic receptors in the bed nucleus of the stria terminalis of rats. Physiol. Behav. 107, 726-732. doi: 10.1016/j.physbeh.2012.05.019.
115. Ma, S., Blasiak, A., Olucha-Bordonau, F. E., Verberne, A. J., and Gundlach, A. L. (2013). Heterogeneous responses of nucleus incertus neurons to corticotropin-releasing factor and coherent activity with hippocampal theta rhythm in the rat. J. Physiol. (Lond.) 591, 3981-4001. doi: 10.1113/jphysiol.2013.254300.
116. Ma, S., Bonaventure, P., Ferraro, T., Shen, P. J., Burazin, T. C. D., Bathgate, R. A. D., et al. (2007). Relaxin-3 in GABA projection neurons of nucleus incertus suggests widespread influence on forebrain circuits via G-protein-coupled receptor-135 in the rat. Neuroscience 144, 165-190. doi: 10.1016/j.neuroscience.2006.08.072.
117. Ma, S., Kastman, H., Olucha-Bordonau, F. E., Capogna, M., Hossain, A., Wade, J. D., et al. (2010). Relaxin-3 receptor activation in the central amygdala enhances fear extinction in the rat: implications for relaxin-3 control of emotion. Soc. Neurosci. Abstr. 809.24.
118. Ma, S., Olucha-Bordonau, F. E., Hossain, M. A., Lin, F., Kuei, C., Liu, C., et al. (2009a). Modulation of hippocampal theta oscillations and spatial memory by relaxin-3 neurons of the nucleus incertus. Learn. Mem. 16, 730-742. doi: 10.1101/lm.1438109.
119. Ma, S., Sang, Q., Lanciego, J. L., and Gundlach, A. L. (2009b). Localization of relaxin-3 in brain of Macaca fascicularis-Identification of nucleus incertus in primate. J. Comp. Neurol. 517, 700-712. doi: 10.1002/cne.22197.
120. Ma, S., Shen, P. J., Sang, Q., Lanciego, J. L., and Gundlach, A. L. (2009c). Distribution of relaxin-3 mRNA and immunoreactivity and RXFP3-binding sites in the brain of the macaque, Macaca fascicularis. Ann. N. Y. Acad. Sci. 1160, 256-258. doi: 10.1111/j.1749-6632.2009.03954.x.
121. Maaswinkel, H., Gispen, W. H., and Spruijt, B. M. (1997). Executive function of the hippocampus in social behavior in the rat. Behav. Neurosci. 111, 777-784. doi: 10.1037/0735-7044.111.4.777.
122. Manji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K., Gray, A. N., et al. (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53, 707-742. doi: 10.1016/S0006-3223(03)00117-3.
123. Marchant, E. G., Watson, N. V., and Mistlberger, R. E. (1997). Both neuropeptide Y and serotonin are necessary for entrainment of circadian rhythms in mice by daily treadmill running schedules. J. Neurosci. 17, 7974-7987.
124. Marder, E. (2012). Neuromodulation of neuronal circuits: back to the future. Neuron 76, 1-11. doi: 10.1016/j.neuron.2012.09.010.
125. Markram, K., and Markram, H. (2010). The intense world theory-a unifying theory of the neurobiology of autism. Front. Hum. Neurosci. 4:224. doi: 10.3389/fnhum.2010.00224.
126. Marson, L., and Foley, K. A. (2004). Identification of neural pathways involved in genital reflexes in the female: a combined anterograde and retrograde tracing study. Neuroscience 127, 723-736. doi: 10.1016/j.neuroscience.2004.04.063.
127. Matsumoto, M., Kamohara, M., Sugimoto, T., Hidaka, K., Takasaki, J., Saito, T., et al. (2000). The novel G-protein coupled receptor SALPR shares sequence similarity with somatostatin and angiotensin receptors. Gene 248, 183-189. doi: 10.1016/S0378-1119(00)00123-2.
128. Mazure, C. M. (1998). Life stressors as risk factors in depression. Clin. Psychol. Sci. Pract. 5, 291-313. doi: 10.1111/j.1468-2850.1998.tb00151.x.
129. McClung, C. A. (2007). Circadian genes, rhythms and the biology of mood disorders. Pharmacol. Ther. 114, 222-232. doi: 10.1016/j.pharmthera.2007.02.003.
130. McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87, 873-904. doi: 10.1152/physrev.00041.2006.
131. McGonigle, P. (2011). Peptide therapeutics for CNS indications. Biochem. Pharmacol. 83, 559-566. doi: 10.1016/j.bcp.2011.10.014.
132. McGowan, B. M., Stanley, S. A., Smith, K. L., Minnion, J. S., Donovan, J., Thompson, E. L., et al. (2006). Effects of acute and chronic relaxin-3 on food intake and energy expenditure in rats. Regul. Peptides 136, 72-77. doi: 10.1016/j.regpep.2006.04.009.
133. McGowan, B. M., Stanley, S. A., Smith, K. L., White, N. E., Connolly, M. M., Thompson, E. L., et al. (2005). Central relaxin-3 administration causes hyperphagia in male Wistar rats. Endocrinology 146, 3295-3300. doi: 10.1210/en.2004-1532.
134. McGowan, B. M., Stanley, S. A., White, N. E., Spangeus, A., Patterson, M., Thompson, E. L., et al. (2007). Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats. Am. J. Physiol. Endocrinol. Metab. 292, E913-E919. doi: 10.1152/ajpendo.00346.2006.
135. McNamara, I. M., Borella, A. W., Bialowas, L. A., and Whitaker-Azmitia, P. M. (2008). Further studies in the developmental hyperserotonemia model (DHS) of autism: social, behavioral and peptide changes. Brain Res. 1189, 203-214. doi: 10.1016/j.brainres.2007.10.063.
136. McNaughton, N., and Gray, J. A. (2000). Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J. Affect. Disord. 61, 161-176. doi: 10.1016/S0165-0327(00)00344-X.
137. McNaughton, N., Kocsis, B., and Hajos, M. (2007). Elicited hippocampal theta rhythm: a screen for anxiolytic and procognitive drugs through changes in hippocampal function? Behav. Pharmacol. 18, 329-346. doi: 10.1097/FBP.0b013e3282ee82e3.
138. Meyer-Bernstein, E. L., and Morin, L. P. (1996). Differential serotonergic innervation of the suprachiasmatic nucleus and the intergeniculate leaflet and its role in circadian rhythm modulation. J. Neurosci. 16, 2097-2111.
139. Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., et al. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 11, 141-168. doi: 10.1038/nrd3628.
140. Miyamoto, Y., Watanabe, Y., and Tanaka, M. (2008). Developmental expression and serotonergic regulation of relaxin 3/INSL7 in the nucleus incertus of rat brain. Regul. Peptides 145, 54-59. doi: 10.1016/j.regpep.2007.08.010.
141. Mogi, K., Nagasawa, M., and Kikusui, T. (2010). Developmental consequences and biological significance of mother-infant bonding. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1232-1241. doi: 10.1016/j.pnpbp.2010.08.024.
142. Möller, C., Sommer, W., Thorsell, A., and Heilig, M. (1999). Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology 21, 507-512. doi: 10.1016/S0893-133X(98)00102-X.
143. Monti, J. M., and Jantos, H. (2008). The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog. Brain Res. 172, 625-646. doi: 10.1016/S0079-6123(08)00929-1.
144. Monti, J. M., and Monti, D. (2000). Sleep disturbance in generalized anxiety disorder and its treatment. Sleep Med. Rev. 4, 263-276. doi: 10.1053/smrv.1999.0096.
145. Morin, L. P. (2013). Neuroanatomy of the extended circadian rhythm system. Exp. Neurol. 243, 4-20. doi: 10.1016/j.expneurol.2012.06.026.
146. Morin, L. P., and Meyer-Bernstein, E. L. (1999). The ascending serotonergic system in the hamster: comparison with projections of the dorsal and median raphe nuclei. Neuroscience 91, 81-105. doi: 10.1016/S0306-4522(98)00585-5.
147. Morin, S. M., Ling, N., Liu, X. J., Kahl, S. D., and Gehlert, D. R. (1999). Differential distribution of urocortin-and corticotropin-releasing factor-like immunoreactivities in the rat brain. Neuroscience 92, 281-291. doi: 10.1016/S0306-4522(98)00732-5.
148. Munro, J., Skrobot, O., Sanyoura, M., Kay, V., Susce, M. T., Glaser, P. E., et al. (2012). Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics. J. Psychopharmacol. 26, 374-379. doi: 10.1177/0269881111408965.
149. Murphy, F. C., Rubinsztein, J. S., Michael, A., Rogers, R. D., Robbins, T. W., Paykel, E. S., et al. (2001). Decision-making cognition in mania and depression. Psychol. Med. 31, 679-693. doi: 10.1017/S0033291701003804.
150. Nakazawa, C. M., Shikata, K., Uesugi, M., Katayama, H., Aoshima, K., Tahara, K., et al. (2013). Prediction of relaxin-3-induced downstream pathway resulting in anxiolytic-like behaviors in rats based on a microarray and peptidome analysis. J. Recept. Signal Transduct. Res. 33, 224-233. doi: 10.3109/10799893.2012.756895.
151. Nawaratne, V., Leach, K., Suratman, N., Loiacono, R. E., Felder, C. C., Armbruster, B. N., et al. (2008). New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 74, 1119-1131. doi: 10.1124/mol.108.049353.
152. Nemeroff, C. B. (1992). New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor. Neuropsychopharmacology 6, 69-75.
153. Nestler, E. J. (1998). Antidepressant treatments in the 21st century. Biol. Psychiatry 44, 526-533. doi: 10.1016/S0006-3223(98)00095-X.
154. Nestler, E. J., and Hyman, S. E. (2010). Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161-1169. doi: 10.1038/nn.2647.
155. Nikisch, G., Baumann, P., Liu, T., and Mathe, A. A. (2011). Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Int. J. Neuropsychopharmacol. 15, 1051-1061. doi: 10.1017/S1461145711001556.
156. Nunez, A., Cervera-Ferri, A., Olucha-Bordonau, F., Ruiz-Torner, A., and Teruel, V. (2006). Nucleus incertus contribution to hippocampal theta rhythm generation. Eur. J. Neurosci. 23, 2731-2738. doi: 10.1111/j.1460-9568.2006.04797.x.
157. Nutt, D. J., Forshall, S., Bell, C., Rich, A., Sandford, J., Nash, J., et al. (1999). Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. 9 S81-S86. doi: 10.1016/S0924-977X(99)00030-9.
158. O'Donnell, P. (2011). Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. Schizophr. Bull. 37, 484-492. doi: 10.1093/schbul/sbr028.
159. Ohnishi, T., Matsuda, H., Hashimoto, T., Kunihiro, T., Nishikawa, M., Uema, T., et al. (2000). Abnormal regional cerebral blood flow in childhood autism. Brain 123 1838-1844. doi: 10.1093/brain/123.9.1838.
160. Olucha-Bordonau, F. E., Otero-Garcia, M., Sanchez-Perez, A. M., Nunez, A., Ma, S., and Gundlach, A. L. (2012). Distribution and targets of the relaxin-3 innervation of the septal area in the rat. J. Comp. Neurol. 520, 1903-1939. doi: 10.1002/cne.23018.
161. Olucha-Bordonau, F. E., Teruel, V., Barcia-Gonzalez, J., Ruiz-Torner, A., Valverde-Navarro, A. A., and Martinez-Soriano, F. (2003). Cytoarchitecture and efferent projections of the nucleus incertus of the rat. J. Comp. Neurol. 464, 62-97. doi: 10.1002/cne.10774.
162. Paez-Pereda, M., Hausch, F., and Holsboer, F. (2011). Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opin. Investig. Drugs 20, 519-535. doi: 10.1517/13543784.2011.565330.
163. Panchal, S. K., and Brown, L. (2011). Rodent models for metabolic syndrome research. J. Biomed. Biotechnol. 35, 1982.
164. Pape, H.-C., Jüngling, K., Seidenbecher, T., Lesting, J., and Reinscheid, R. K. (2010). Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology 58, 29-34. doi: 10.1016/j.neuropharm.2009.06.001.
165. Peca, J., Feliciano, C., Ting, J. T., Wang, W., Wells, M. F., Venkatraman, T. N., et al. (2011). Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472, 437-442. doi: 10.1038/nature09965.
166. Pekala, D., Blasiak, T., Raastad, M., and Lewandowski, M. H. (2011). The influence of orexins on the firing rate and pattern of rat intergeniculate leaflet neurons-electrophysiological and immunohistological studies. Eur. J. Neurosci. 34, 1406-1418. doi: 10.1111/j.1460-9568.2011.07868.x.
167. Pereira, C. W., Santos, F. N., Sanchez-Perez, A. M., Otero-Garcia, M., Marchioro, M., Ma, S., et al. (2013). Electrolytic lesion of the nucleus incertus retards extinction of auditory conditioned fear. Behav. Brain Res. 247, 201-210. doi: 10.1016/j.bbr.2013.03.025.
168. Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., et al. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015.
169. Pulga, A., Ruzza, C., Rizzi, A., Guerrini, R., and Calo, G. (2012). Anxiolytic-and panicolytic-like effects of neuropeptide S in the mouse elevated T-maze. Eur. J. Neurosci. 36, 3531-3537. doi: 10.1111/j.1460-9568.2012.08265.x.
170. Rajkumar, R., See, L. K., and Dawe, G. S. (2013). Acute antipsychotic treatments induce distinct c-Fos expression patterns in appetite-related neuronal structures of the rat brain. Brain Res. 1508, 34-43. doi: 10.1016/j.brainres.2013.02.050.
171. Ressler, K. J., Mercer, K. B., Bradley, B., Jovanovic, T., Mahan, A., Kerley, K., et al. (2011). Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470, 492-497. doi: 10.1038/nature09856.
172. Ring, R. H. (2011). A complicated picture of oxytocin action in the central nervous system revealed. Biol. Psychiatry 69, 818-819. doi: 10.1016/j.biopsych.2011.03.020.
173. Rosengren, K. J., Lin, F., Bathgate, R. A. D., Tregear, G. W., Daly, N. L., Wade, J. D., et al. (2006). Solution structure and novel insights into the determinants of the receptor specificity of human relaxin-3. J. Biol. Chem. 281, 5845-5851. doi: 10.1074/jbc.M511210200.
174. Rotzinger, S., Lovejoy, D. A., and Tan, L. A. (2010). Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 31, 736-756. doi: 10.1016/j.peptides.2009.12.015.
175. Roux, L., and Donaldson, C. (2012). Economics and obesity: costing the problem or evaluating solutions? Obes. Res. 12, 173-179. doi: 10.1038/oby.2004.23.
176. Russo, S. J., and Nestler, E. J. (2013). The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609-625. doi: 10.1038/nrn3381.
177. Ryan, P. J., Buchler, E., Shabanpoor, F., Hossain, M. A., Wade, J. D., Lawrence, A. J., et al. (2013a). Central relaxin-3 receptor (RXFP3) activation decreases anxiety-and depressive-like behaviours in the rat. Behav. Brain Res. 244, 142-151. doi: 10.1016/j.bbr.2013.01.034.
178. Ryan, P. J., Kastman, H. E., Krstrew, E. V., Chirlov, L., Rosengren, K. J., Hossain, M. A., et al. (2013b). Relaxin-3/RXFP3 system regulates alcohol-seeking. Proc. Natl. Acad. Sci. U.S.A. 110, 20789-20794. doi: 10.1073/pnas.1317807110.
179. Ryan, P. J., Ma, S., Olucha-Bordonau, F. E., and Gundlach, A. L. (2011). Nucleus incertus-an emerging modulatory role in arousal, stress and memory. Neurosci. Biobehav. Rev. 35, 1326-1341. doi: 10.1016/j.neubiorev.2011.02.004.
180. Saito, Y., and Nagasaki, H. (2008). The melanin-concentrating hormone system and its physiological functions. Results Probl. Cell Differ. 46, 159-179. doi: 10.1007/400_2007_052.
181. Sakurai, T. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8, 171-181. doi: 10.1038/nrn2092.
182. Sanogo, Y. O., Hankison, S., Band, M., Obregon, A., and Bell, A. M. (2011). Brain transcriptomic response of threespine sticklebacks to cues of a predator. Brain Behav. Evol. 77, 270-285. doi: 10.1159/000328221.
183. Saper, C. B., Scammell, T. E., and Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature 437, 1257-1263. doi: 10.1038/nature04284.
184. Sasaki, K., Suzuki, M., Mieda, M., Tsujino, N., Roth, B., and Sakurai, T. (2011). Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS ONE 6:e20360. doi: 10.1371/journal.pone.0020360.
185. Schmidt, H. D., and Duman, R. S. (2010). Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 35, 2378-2391. doi: 10.1038/npp.2010.114.
186. Shabanpoor, F., Akhter Hossain, M., Ryan, P. J., Belgi, A., Layfield, S., Kocan, M., et al. (2012). Minimization of human relaxin-3 leading to high-affinity analogues with increased selectivity for relaxin-family peptide 3 receptor (RXFP3) over RXFP1. J. Med. Chem. 55, 1671-1681. doi: 10.1021/jm201505p.
187. Sherwood, O. D. (2004). Relaxin's physiological roles and other diverse actions. Endocr. Rev. 25, 205-234. doi: 10.1210/er.2003-0013.
188. Shinohara, K., Tominaga, K., Isobe, Y., and lnouye, S.-I. T. (1993). Photic regulation of peptides located in the ventrolateral subdivision of the suprachiasmatic nucleus of the rat: daily variations of vasoactive intestinal polypeptide, gastrin-releasing peptide, and neuropeptide Y. J. Neurosci. 13, 793-800.
189. Silverman, J. L., Tolu, S. S., Barkan, C. L., and Crawley, J. N. (2010). Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35, 976-989. doi: 10.1038/npp.2009.201.
190. Smith, C. M., Blasiak, A., Ganella, D. E., Chua, B. E., Layfield, S. L., Bathgate, R. A. D., et al. (2013a). "Viral-mediated delivery of an RXFP3 agonist into brain promotes arousal in mice," in Proceedings of Sixth International Conference on Relaxin and Related Peptides, Florence.
191. Smith, C. M., Chua, B. E., Walker, A. W., and Gundlach, A. L. (2013b). "Potential hypothalamic targets of relaxin-3 innervation: a perspective," in Proceedings of Sixth International Conference on Relaxin and Related Peptides, Florence.
192. Smith, C. M., Hosken, I. T., Sutton, S. W., Lawrence, A. J., and Gundlach, A. L. (2012). Relaxin-3 null mutation mice display a circadian hypoactivity phenotype. Genes Brain Behav. 11, 94-104. doi: 10.1111/j.1601-183X.2011.00730.x.
193. Smith, C. M., Lawrence, A. J., Sutton, S. W., and Gundlach, A. L. (2009). Behavioral phenotyping of mixed-background (129S5:B6) relaxin-3 knockout mice. Ann. N. Y. Acad. Sci. 1160, 236-241. doi: 10.1111/j.1749-6632.2009.03953.x.
194. Smith, C. M., Ryan, P. J., Hosken, I. T., Ma, S., and Gundlach, A. L. (2011). Relaxin-3 systems in the brain-the first 10 years. J. Chem. Neuroanat. 42, 262-275. doi: 10.1016/j.jchemneu.2011.05.013.
195. Smith, C. M., Shen, P. J., Banerjee, A., Bonaventure, P., Ma, S., Bathgate, R. A. D., et al. (2010). Distribution of relaxin 3 and RXFP3 within arousal, stress, affective, and cognitive circuits of mouse brain. J. Comp. Neurol. 518, 4016-4045. doi: 10.1002/cne.22442.
196. Smith, K. L., Patterson, M., Dhillo, W. S., Patel, S. R., Semjonous, N. M., Gardiner, J. V., et al. (2006). Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology 147, 3510-3518. doi: 10.1210/en.2005-1280.
197. Sodersten, P., Bergh, C., and Zandian, M. (2006). Understanding eating disorders. Horm. Behav. 50, 572-578. doi: 10.1016/j.yhbeh.2006.06.030.
198. Spencer, K. M., Nestor, P. G., Niznikiewicz, M. A., Salisbury, D. F., Shenton, M. E., and McCarley, R. W. (2003). Abnormal neural synchrony in schizophrenia. J. Neurosci. 23, 7407-7411.
199. Steinbusch, H. W. (1981). Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6, 557-618. doi: 10.1016/0306-4522(81)90146-9.
200. Sutton, S. W., Bonaventure, P., Kuei, C., Roland, B., Chen, J., Nepomuceno, D., et al. (2004). Distribution of G-protein-coupled receptor (GPCR)135 binding sites and receptor mRNA in the rat brain suggests a role for relaxin-3 in neuroendocrine and sensory processing. Neuroendocrinology 80, 298-307. doi: 10.1159/000083656.
201. Sutton, S. W., Shelton, J., Smith, C., Williams, J., Yun, S., Motley, T., et al. (2009). Metabolic and neuroendocrine responses to RXFP3 modulation in the central nervous system. Ann. N. Y. Acad. Sci. 1160, 242-249. doi: 10.1111/j.1749-6632.2008.03812.x.
202. Takagi, H., Shiosaka, S., Tohyama, M., Senba, E., and Sakanaka, M. (1980). Ascending components of the medial forebrain bundle from the lower brain stem in the rat, with special reference to raphe and catecholamine cell groups. A study by the HRP method. Brain Res. 193, 315-337. doi: 10.1016/0006-8993(80)90168-7.
203. Tanaka, M. (2010). Relaxin-3/insulin-like peptide 7, a neuropeptide involved in the stress response and food intake. FEBS J. 277, 4990-4997. doi: 10.1111/j.1742-4658.2010.07931.x.
204. Tanaka, M., Iijima, N., Miyamoto, Y., Fukusumi, S., Itoh, Y., Ozawa, H., et al. (2005). Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stress. Eur. J. Neurosci. 21, 1659-1670. doi: 10.1111/j.1460-9568.2005.03980.x.
205. Tanaka, M., Watanabe, Y., and Yoshimoto, K. (2009). Regulation of relaxin 3 gene expression via cAMP-PKA in a neuroblastoma cell line. J. Neurosci. Res. 87, 820-829. doi: 10.1002/jnr.21895.
206. Tandon, R. (2011). Antipsychotics in the treatment of schizophrenia: an overview. J. Clin. Psychiatry 72(Suppl. 1), 4-8. doi: 10.4088/JCP.10075su1.01.
207. Teruel-Marti, V., Cervera-Ferri, A., Nunez, A., Valverde-Navarro, A. A., Olucha-Bordonau, F. E., and Ruiz-Torner, A. (2008). Anatomical evidence for a ponto-septal pathway via the nucleus incertus in the rat. Brain Res. 1218, 87-96. doi: 10.1016/j.brainres.2008.04.022.
208. Thankachan, S., and Rusak, B. (2005). Juxtacellular recording/labeling analysis of physiological and anatomical characteristics of rat intergeniculate leaflet neurons. J. Neurosci. 25, 9195-9204. doi: 10.1523/JNEUROSCI.2672-05.2005.
209. Theisen, F. M., Linden, A., Konig, I. R., Martin, M., Remschmidt, H., and Hebebrand, J. (2003). Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J. Neural Transm. 110, 111-121.
210. Vaccari, C., Lolait, S. J., and Ostrowski, N. L. (1998). Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 139, 5015-5033.
211. Van Cauter, E., Linkowski, P., Kerkhofs, M., Hubain, P., L'Hermite-Baleriaux, M., Leclercq, R., et al. (1991). Circadian and sleep-related endocrine rhythms in schizophrenia. Arch. Gen. Psychiatry 48, 348. doi: 10.1001/archpsyc.1991.01810280064009.
212. van den Pol, A. N. (2012). Neuropeptide transmission in brain circuits. Neuron 76, 98-115. doi: 10.1016/j.neuron.2012.09.014.
213. van der Westhuizen, E. T., Christopoulos, A., Sexton, P. M., Wade, J. D., and Summers, R. J. (2010). H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3). Mol. Pharmacol. 77, 759-772. doi: 10.1124/mol.109.061432.
214. van der Westhuizen, E. T., Werry, T. D., Sexton, P. M., and Summers, R. J. (2007). The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism. Mol. Pharmacol. 71, 1618-1629. doi: 10.1124/mol.106.032763.
215. van Elst, L. T., Woermann, F. G., Lemieux, L., Thompson, P. J., and Trimble, M. R. (2000). Affective aggression in patients with temporal lobe epilepsy: a quantitative MRI study of the amygdala. Brain 123, 234-243. doi: 10.1093/brain/123.2.234.
216. Van Pett, K., Viau, V., Bittencourt, J. C., Chan, R. K., Li, H. Y., Arias, C., et al. (2000). Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 428, 191-212. doi: 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U.
217. Vertes, R. P., and Kocsis, B. (1997). Brainstem-diencephalo-septohippocampal systems controlling the theta rhythm of the hippocampus. Neuroscience 81, 893-926.
218. Vianna, D. M., Graeff, F. G., Landeira-Fernandez, J., and Brandao, M. L. (2001). Lesion of the ventral periaqueductal gray reduces conditioned fear but does not change freezing induced by stimulation of the dorsal periaqueductal gray. Learn. Mem. 8, 164-169. doi: 10.1101/lm.36101.
219. Videbech, P., and Ravnkilde, B. (2004). Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 161, 1957-1966. doi: 10.1176/appi.ajp.161.11.1957.
220. Vithlani, M., Hines, R. M., Zhong, P., Terunuma, M., Hines, D. J., Revilla-Sanchez, R., et al. (2013). The ability of BDNF to modify neurogenesis and depressive-like behaviors is dependent upon phosphorylation of tyrosine residues 365/367 in the GABAA-receptor γ2 subunit. J. Neurosci. 33, 15567-15577. doi: 10.1523/JNEUROSCI.1845-13.2013.
221. von Euler, U. S., and Gaddum, J. H. (1931). An unidentified depressor substance in certain tissue extracts. J. Physiol. 72, 74.
222. Walker, D. L., Miles, L. A., and Davis, M. (2009). Selective participation of the bed nucleus of the stria terminalis and CRF in sustained anxiety-like vs. phasic fear-like responses. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1291-1308. doi: 10.1016/j.pnpbp.2009.06.022.
223. Wang, X. J. (2002). Pacemaker neurons for the theta rhythm and their synchronization in the septohippocampal reciprocal loop. J. Neurophysiol. 87, 889-900.
224. Watanabe, Y., Miyamoto, Y., Matsuda, T., and Tanaka, M. (2011a). Relaxin-3/INSL7 regulates the stress-response system in the rat hypothalamus. J. Mol. Neurosci. 43, 169-174. doi: 10.1007/s12031-010-9468-0.
225. Watanabe, Y., Tsujimura, A., Takao, K., Nishi, K., Ito, Y., Yasuhara, Y., et al. (2011b). Relaxin-3-deficient mice showed slight alteration in anxiety-related behavior. Front. Behav. Neurosci. 5:50. doi: 10.3389/fnbeh.2011.00050.
226. Wess, J., Nakajima, K., and Jain, S. (2013). Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol. Sci. 34, 385-392. doi: 10.1016/j.tips.2013.04.006.
227. Westenberg, H. G. (1999). Pharmacology of antidepressants: selectivity or multiplicity? J. Clin. Psychiatry 60(Suppl. 17), 4-8.
228. Wilkinson, T. N., Speed, T. P., Tregear, G. W., and Bathgate, R. A. D. (2005). Evolution of the relaxin-like peptide family. BMC Evol. Biol. 5:14. doi: 10.1186/1471-2148-5-14.
229. Willard, S. L., and Shively, C. A. (2012). Modeling depression in adult female cynomolgus monkeys (Macaca fascicularis). Am. J. Primatol. 74, 528-542. doi: 10.1002/ajp.21013.
230. Willner, P., Scheel-Krüger, J., and Belzung, C. (2013). The neurobiology of depression and antidepressant action. Neurosci. Biobehav. Rev. 37, 2331-2371. doi: 10.1016/j.neubiorev.2012.12.007.
231. Winrow, C. J., and Renger, J. J. (2014). Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br. J. Pharmacol. 171, 283-293. doi: 10.1111/bph.12261.
232. Xu, Y. L., Reinscheid, R. K., Huitron-Resendiz, S., Clark, S. D., Wang, Z., Lin, S. H., et al. (2004). Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43, 487-497. doi: 10.1016/j.neuron.2004.08.005.
233. Yamasue, H., Yee, J. R., Hurlemann, R., Rilling, J. K., Chen, F. S., Meyer-Lindenberg, A., et al. (2012). Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction. J. Neurosci. 32, 14109-14117. doi: 10.1523/JNEUROSCI.3327-12.2012.
234. Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M., and Deisseroth, K. (2011a). Optogenetics in neural systems. Neuron 71, 9-34. doi: 10.1016/j.neuron.2011.06.004.
235. Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O'Shea, D. J., et al. (2011b). Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477, 171-178. doi: 10.1038/nature10360.
236. Yoshida, M., Takayanagi, Y., Inoue, K., Kimura, T., Young, L. J., Onaka, T., et al. (2009). Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J. Neurosci. 29, 2259-2271. doi: 10.1523/JNEUROSCI.5593-08.2009.
237. Zee, P. C., and Manthena, P. (2007). The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med. Rev. 11, 59-70. doi: 10.1016/j.smrv.2006.06.001.
238. Zhang, F., Gradinaru, V., Adamantidis, A. R., Durand, R., Airan, R. D., de Lecea, L., et al. (2010). Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. Nat. Protoc. 5, 439-456. doi: 10.1038/nprot.2009.226.
239. Zhang, J., Fan, Y., Li, Y., Zhu, H., Wang, L., and Zhu, M. Y. (2012). Chronic social defeat up-regulates expression of the serotonin transporter in rat dorsal raphe nucleus and projection regions in a glucocorticoid-dependent manner. J. Neurochem. 123, 1054-1068. doi: 10.1111/jnc.12055.
240. Zheng, H., and Rinaman, L. (2013). Yohimbine anxiogenesis in the elevated plus maze requires hindbrain noradrenergic neurons that target the anterior ventrolateral bed nucleus of the stria terminalis. Eur. J. Neurosci. 37, 1340-1349. doi: 10.1111/ejn.12123.
241. Zorrilla, E. P., Heilig, M., de Wit, H., and Shaham, Y. (2013). Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 128, 175-186. doi: 10.1016/j.drugalcdep.2012.12.017.
242. Zorrilla, E. P., and Koob, G. F. (2010). Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov. Today 15, 371-383. doi: 10.1016/j.drudis.2010.02.011.